Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer

Oropharynx Squamous Cell Carcinoma

Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

16 Active assets in the Oropharynx Squamous Cell Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Cetuximab National Cancer Institute (NCI)	Phase 1/2	B
Irinotecan AIDS Malignancy Consortium	Phase 1/2	B
e7 tcr-t cells Christian Hinrichs	Phase 2	B
Cis-Diamminedichloroplatinum Ii ImmunityBio, Inc.	Phase 2	CCC
Nivolumab National Cancer Institute (NCI)	Phase 2	CCC

View all 31 →

Same molecule, other indications

Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer is also rated in:

skin squamous cell carcinomaActive

Indicative · Phase 3

66 / 100

View asset →

lung cancerActive

Indicative · Phase 2/3

65 / 100

View asset →

nonpapillary renal cell carcinomaActive

Indicative · Phase 2

65 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →